👉 The start of a new year creates a natural moment for reflection and recalibration. Budgets are reviewed. Scientific priorities are discussed. Fundraising timelines are adjusted. Yet one decision often remains unchanged from the previous year. 👉 Patent strategy is treated as something already decided rather than something that deserves fresh leadership attention . For smart biotech CEOs, this is a missed opportunity. A company does not enter January in the same position it